PARP inhibitors are a promising therapy in cancer treatment, having already demonstrated their beneficial effects in the treatment of ovarian cancer patients with specific deficiencies in homologous recombination-mediated DNA repair. This evidence concerns the gene PARP1 and ovarian cancer.